Literature DB >> 7900436

Experimental cerebral malaria: possible new mechanisms in the TNF-induced microvascular pathology.

G E Grau1, J N Lou.   

Abstract

In order to contribute to the prevention of malaria morbidity and mortality, especially in endemic zones, we have carried out a series of studies on cytokine interactions in an experimental model of cerebral malaria (CM). This rapidly lethal syndrome develops, in some strains of mice, upon infection with Plasmodium berghei ANKA (PbA). A crucial mediator of neurovascular lesions appears to be TNF, found in high amounts in relation with cerebral complications, in both experimental and human CM. In experimental CM, in vivo injections of anti-cytokine antibodies have been used to analyze the cascade of reactions leading to brain vascular damage. In this review, we fill focus on the interplay of cytokines responsible for TNF overproduction in experimental malaria, therefore delineating the subset of T cells whose activation can lead to pathology, and effector mechanisms of neurovascular lesions characteristic of mouse cerebral malaria, with recent findings that appear to involve an unexpected cell type, the blood platelet.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7900436     DOI: 10.1007/bf01615662

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  36 in total

1.  THE MECHANISM OF THE ENDOTHELIAL SUPPORTING FUNCTION OF INTACT PLATELETS.

Authors:  S A JOHNSON; R S BALBOA; B H DESSEL; R W MONTO; K A SIEGESMUND; T J GREENWALT
Journal:  Exp Mol Pathol       Date:  1964-04       Impact factor: 3.362

Review 2.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria.

Authors:  G E Grau; P F Piguet; H D Engers; J A Louis; P Vassalli; P H Lambert
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

Review 4.  Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data.

Authors:  G E Grau; P F Piguet; P Vassalli; P H Lambert
Journal:  Immunol Rev       Date:  1989-12       Impact factor: 12.988

5.  Late treatment with anti-LFA-1 (CD11a) antibody prevents cerebral malaria in a mouse model.

Authors:  P B Falanga; E C Butcher
Journal:  Eur J Immunol       Date:  1991-09       Impact factor: 5.532

6.  Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation.

Authors:  G E Grau; V Kindler; P F Piguet; P H Lambert; P Vassalli
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

Review 7.  Interaction of platelets and blood vessels--vascular injuries induced by platelet activation in vivo.

Authors:  H Yamazaki; T Fujimoto; H Suzuki; N Akamatsu; Y Katagiri; A Yamaguchi; K Tanoue
Journal:  Jpn Circ J       Date:  1992-02

8.  An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium.

Authors:  P F Piguet; C Vesin; J E Ryser; G Senaldi; G E Grau; F Tacchini-Cottier
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies.

Authors:  P F Piguet; H Rosen; C Vesin; G E Grau
Journal:  Am Rev Respir Dis       Date:  1993-02

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  6 in total

1.  Cytokine profile suggesting that murine cerebral malaria is an encephalitis.

Authors:  V M Jennings; J K Actor; A A Lal; R L Hunter
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

2.  Beta interferon suppresses the development of experimental cerebral malaria.

Authors:  Craig N Morrell; Kalyan Srivastava; Annemarie Swaim; M Teresa Lee; Jun Chen; Chandrashakaharam Nagineni; John J Hooks; Barbara Detrick
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

3.  Evidence for multiple pathologic and protective mechanisms of murine cerebral malaria.

Authors:  V M Jennings; A A Lal; R L Hunter
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

4.  TNF-α Triggers RIP1/FADD/Caspase-8-Mediated Apoptosis of Astrocytes and RIP3/MLKL-Mediated Necroptosis of Neurons Induced by Angiostrongylus cantonensis Infection.

Authors:  Hongli Zhou; Minyu Zhou; Yue Hu; Yanin Limpanon; Yubin Ma; Ping Huang; Paron Dekumyoy; Wanchai Maleewong; Zhiyue Lv
Journal:  Cell Mol Neurobiol       Date:  2021-03-08       Impact factor: 4.231

5.  A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI.

Authors:  Constantin von Zur Muhlen; Nicola R Sibson; Karlheinz Peter; Sandra J Campbell; Panop Wilainam; Georges E Grau; Christoph Bode; Robin P Choudhury; Daniel C Anthony
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

6.  Lipoxin A₄ and 15-epi-lipoxin A₄ protect against experimental cerebral malaria by inhibiting IL-12/IFN-γ in the brain.

Authors:  Nathaniel Shryock; Cortez McBerry; Rosa Maria Salazar Gonzalez; Steven Janes; Fabio T M Costa; Julio Aliberti
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.